SP-02L (darinaparsin for injection)

DRUG3 trials

Sponsors

Solasia Pharma K.K.

Conditions

Peripheral T-Cell LymphomaPeripheral T-cell Lymphoma

Phase 1

A Phase 1 Study of SP-02L in Relapsed or Refractory Patients With Peripheral T-cell Lymphoma (PTCL)

CompletedNCT01435863

Solasia Pharma K.K.Peripheral T-cell Lymphoma

Start: 2011-09-30End: 2015-07-31Updated: 2015-08-13

A Phase 1 Study of SP-02L in Relapsed or Refractory Patients With Peripheral T-cell Lymphoma (PTCL) in Korea

CompletedNCT01689220

Solasia Pharma K.K.Peripheral T-cell Lymphoma

Start: 2012-09-30End: 2014-09-30Updated: 2014-09-04

Phase 2

A Phase 2 Study of SP-02L in Patients With Relapsed or Refractory Peripheral T-cell Lymphoma (PTCL)

CompletedNCT02653976

Solasia Pharma K.K.Peripheral T-Cell Lymphoma

Start: 2016-03-25End: 2021-06-17Updated: 2024-01-26

Related Papers

Darinaparsin in patients with relapsed or refractory peripheral T-cell lymphoma: results of an Asian phase 2 study

Blood Advances2023-01-2010 citations

Phase I studies of darinaparsin in patients with relapsed or refractory peripheral T-cell lymphoma: a pooled analysis of two phase I studies conducted in Japan and Korea

Japanese Journal of Clinical Oncology2020-09-0215 citations